Clearmind Medicine Announces 1-for-40 Reverse Share Split

Vancouver, Canada, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-40. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing December 15, 2025.
‍
The reverse share split was approved by the Company' board of directors on November 12, 2025, in accordance with the Company’s articles of association.
‍
Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged, which as of the date hereof is unlimited. The reverse split will adjust the number of issued and outstanding Common Shares of the Company from 59,991,852 Common Shares to 1,499,796 Common Shares (subject to any further adjustments based on the treatment of fractional shares).
‍
No fractional Common Shares will be issued as a result of the reverse split. All fractional shares shall be rounded up to the nearest whole Common Share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of Common Shares issuable upon the exercise of all outstanding options or warrants entitling the holders thereof to purchase Common Shares.
About Clearmind Medicine Inc.

Read more at globenewswire.com